Introduction
Infections remain among the most important concerns in critically ill patients. Early and reliable diagnosis of infection still poses diffi culties in this setting but also represents a crucial step toward an appropriate antimicrobial therapy that avoids the perils of excessive antibiotic exposure. Increasing antimicrobial resistance chal lenges established approaches to the optimal manage ment of infections in the intensive care unit (ICU). Rapid infection diagnosis, antibiotic dosing and optimization through pharmacologic indices, progress in the imple mentation of eff ective antimicrobial stewardship pro grams, and management of fungal infections are some of the most relevant issues in this special patient population. Here, we briefl y review the results from selected studies published on those topics in 2010 and take a special interest in articles published in Critical Care. Other important subjects like H1N1 infl uenza virus infection and prevention of nosocomial infection were discussed in last year's review in Critical Care [1] and will be summarized only briefl y.
Rapid infection diagnosis: novel technologies and biomarkers
Since they detect viable microorganisms that can be further characterized by molecular or biochemical techniques, blood cultures are still considered the gold standard to diagnose bloodstream infection (BSI) and to identify the species and determine their antimicrobial susceptibility. However, blood cultures are far from being an ideal gold standard as they often provide results with delay, are incomplete, and may not refl ect all microbiological evidence important for clinical decision making [2] . Recent technological advances such as the development of fully automated instruments and the application of matrix-assisted laser desorption ionization time-of-fl ight mass spectrometry (MALDI-TOF) have reduced identi fi cation time to 4 hours, once blood cultures have become positive [3] . Various technologies based on nucleic acid extraction (nucleic acid testing) from positive blood cultures hold some promise [4] . A microarray-based, commercially available molecular assay for sepsis detection (Prove-it Sepsis; Mobidiag, Helsinki, Finland) was recently evaluated in a large observational multicenter study [5] . Th e main shortcomings of these techniques are the inability to be applied directly to biological samples, the need for prior cultivation of the pathogen, and the relatively high costs.
Several automated platforms that are either commercially available or under development aim to directly detect bacteria or fungi in blood without prior cultivation [6] . Multiplex real-time polymerase chain reaction (PCR) assays and microarrays are the most promising approaches for rapid direct identifi cation of pathogens from blood. A real-time multiplex PCR-based assay widely available for BSI diagnosis is the SeptiFast kit (Roche, Basel, Switzerland), which can detect 25 clinically important bacteria and fungi at the species level directly from whole blood in about 6 hours. However, this kit requires a great deal of labor and expertise and is
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Pharmacokinetics and pharmacodynamics for optimized antimicrobial dosing
Knowledge of pharmacokinetics (PK) and pharmacodynamics (PD) is important for antimicrobial dosing regimens that can maximize the therapeutic eff ects and conceivably reduce the development of antimicrobial resistance. Th is knowledge is required mostly for patients in the ICU. A few years ago, Pea and colleagues [15] demonstrated that many physiopathological factors may aff ect antimicrobial plasma concentration in critically ill patients: overexposure to hydrophilic or lipophilic antimicrobials may occur during acute renal failure or severe liver insuffi ciency; conversely, under exposure may be due to increased volume of distribution (for example, ascites, edema, and mediasti nitis) or to increased renal fi ltration (for example, hyperdynamic conditions during sepsis or hypoalbumin emia). Indeed, Giannoni and colleagues [16] showed that up to 30% of patients may be underdosed and thus successful outcomes may be impaired and antimicrobial resistance promoted. For example, in patients with severe sepsis, hypoalbuminemia occurs frequently as a conse quence of either increased capillary escape rate through leaky endothelium or fl uid overload. By increasing the unbound fraction, hypoalbuminemia may promote not only a more extensive distribution but also greater renal clearance [17] . Th is may lead to underdosing in critically ill patients whenever highly protein-bound antimicrobials (that is, teicoplanin, ertapenem, or ceftriaxone) are used.
Th e increased importance of PK and PD parameters strengthens the relationship with prospective monitoring of minimal inhibitory concentration (MIC) of bacterial strains at the local level. Indeed, to achieve better clinical outcomes, the target concentration attainment should be based on the ratio between optimized antimicrobial dosing and the MIC of the pathogen involved in the infec tion [18] . According to the two most important mecha nisms of action of antimicrobials (that is, concentrationdependent and time-dependent), maximal drug effi cacy could be achieved through an optimized peak concen tration (C max )/MIC ratio for the former (aminoglycosides and quinolones) and a time-curve over MIC (t >MIC) for the latter (β-lactams, carbapenems, and vancomycin).
Optimal antibacterial activity of concentrationdependent antimicrobials is achieved when the C max is 8 to 10 times greater than the MIC. Taccone and colleagues [19] confi rmed the hypothesis that, in critically ill patients, increased volume of distribution (V d ) of hydrophilic drugs aff ects the disposition of aminoglyco sides and therefore a revisited amikacin loading dose of 25 mg/kg should be required to attain the target concentration and the optimized C max /MIC ratio. Th ese fi ndings parallel a recent experience by the same group [20] , in which sepsis due to panresistant P. aeruginosa (amikacin MIC = 16 mg/L) was successfully treated with amikacin monotherapy once amikacin C max attained 160 mg/L under continuous venovenous hemodia fi ltration (C max /MIC ratio = 10). Other recent papers on aminoglycoside dosing and disposition seem to confi rm those fi ndings [21, 22] . Lastly, high-dosage, short-course therapy regimens with concen tra tion-dependent antibiotics through a once-daily adminis tration schedule may yield a more rapid bacterial killing or prevention of resistance development.
For time-dependent antimicrobials, the PD parameter most predictive of maximal bactericidal activity is the duration of time in which free drug concentrations remain above the MIC during the dosing interval (ƒT >MIC). Time-dependent antimicrobials -β-lactams, carbapenems, and vancomycin -are hydrophilic substances, and their disposition is greatly aff ected by several factors that are frequently encountered in critically ill patients [17, [23] [24] [25] : variation in V d by capillary leak syndrome, massive fl uid replacement, and hypoalbumine mia or by increased third space (for example, drainages, ascites, pleural eff usions, and mediastinitis) as well as hyper dynamic status, vasoactive and diuretic drugs, and varia tion in glomerular fi ltration rate. Even though adjusting the meropenem dosage for renal function and prolonging the infusion in such patients may provide an improved target attainment of ƒT >MIC [26] , other recent experiences have confi rmed how most of the aforementioned conditions may substantially impair the eff ective concen tra tion of hydrophilic antimicrobials [27] [28] [29] [30] [31] [32] . By optimiz ing antibiotic doses to achieve PD targets predictive of effi cacy, clinicians can improve care and minimize drug toxicity provided that careful therapeutic drug monitor ing is carried out [33] . Unfortunately, the conventional intermittent β-lactam dosing schemes often used in ICU practice have suboptimal PD profi les. Prolonging the infusion time of β-lactams is one method to maximize the probability of achieving concentrations in excess of the MIC for the majority of the dosing interval, especially against pathogens with elevated MIC values [17, 28, 29] . Prolonged infusions of intravenous β-lactams not only are associated with improved probability of target attain ment profi les but off er possible cost savings and greater potential for reducing the emergence of resistance relative to intermittent infusions [34] .
Since these new approaches are not yet fi rmly confi rmed, several ongoing clinical studies are now applying the clinical pharmacology parameters to real practice; probably, these studies will off er new insights into the appropriateness of antimicrobial therapy in the ICU. Until the results of these studies are published, it is mandatory that ICU physicians conduct a daily reassessment of antimicrobial regimens in accordance with the daily measurement of creatinine clearance and other variables aff ecting PK and keep in mind that the assessment of renal function can identify not only patients with renal impairment at risk for drug toxicity but also those with glomerular hyperfi ltration or increased V d , in whom higher dosages are bound to be administered.
Antimicrobial resistance, infection control, and antimicrobial stewardship programs
Antimicrobial resistance (AMR) is increasing worldwide [35] . In a multicenter study performed by Meyer and colleagues [8] between 2001 and 2008 in 53 German ICUs, carbapenem use almost doubled despite the absence of signifi cant change in total antibiotic use expressed as defi ned daily doses per 1,000 patient-days. Th e exponential increase of third-generation cephalosporin resistance in Escherichia coli and other Enterobacteriaceae reported in that study led to switching empirical therapy to carbapenems to treat infections, and carbapenem-resistant Klebsiella pneumoniae, carbapenemase-producing Gram-negative pathogens, and imipenemresistant Acinetobacter baumannii emerged as a direct consequence. Th is scenario will aff ect many ICUs in Europe in the near future. However, resistance trends and antibiotic consumption rates will depend on diff erent factors, including ICU characteristics (medical, surgical, and general), local antibiotic policies, and physicians' level of education. Th e heterogeneity of antibiotic prescrip tions within ICUs, as recorded by Meyer and colleagues [8] , seems to indicate that antimicrobial use can be improved in ICU settings by shortening the duration of treatment or antibiotic prophylaxis without aff ecting patient outcome. In this respect, Morel and colleagues [36] showed how de-escalation could be one of several eff ective strategies for a more appropriate empirical therapy. However, the retrospective design of the study and the delay in de-escalation (more than 3 days on average) from the onset of infection limit the power of the study. Moreover, as clearly pointed out in the same study, it was not possible to draw fi rm conclusions on the impact of this strategy on AMR. Adherence to shared protocols or local guidelines, on the basis of local epidemiology of resistance and control of antibiotic prescriptions, may reverse the trend of AMR (especially in MRSA), whereas it appears more diffi cult for Gram-negative pathogens [37] [38] [39] [40] . Th e fi ndings of Meyer and colleagues [8] reaffi rm the concern that Gram-negative pathogens could become even more intractable day by day and are paralleled by the fi ndings of Augustin and colleagues [41] , indicating that, at this time, only imipenem/cilastatin can be considered an adequate single-drug empirical therapy for postoperative peritonitis. Not surprisingly, in the latter study, use of broad-spectrum antimicrobials between initial inter vention and reoperation was the only signifi cant risk factor for the emergence of multidrug-resistant patho gens in critically ill patients with postoperative peritonitis [41] .
To challenge such situations, a multitasked approach is needed [42, 43] . Th e combination of a comprehensive infection control strategy and an eff ective antimicrobial stewardship program (ASP) may lead to the prevention of emergence and transmission of resistant pathogens [42] . Th is includes multimodal strategies, variably combined, such as hand hygiene promotion, barrier precautions and asymptomatic patient decolonization, prevention bundles, and environmental decontamination [44] . Recently, two important studies have highlighted not only the eff orts in prevention of resistant pathogens but also the diffi culties in gaining sustained and reproducible results [45, 46] . Jain and colleagues [45] evaluated the eff ectiveness of a quality improvement initiative in prevent ing the acquisition and spread of MRSA among nearly 2 million patient admissions; the study included data from 196 ICUs in the US. During the intervention period -with increased attention to MRSA admission screening, contact precau tions, hand hygiene, and emphasis on the responsibility of all health-care workers in prevention procedures -an important decrease in infections caused not only by MRSA but also by other pathogens was observed [45] . Huskins and colleagues [46] evaluated more than 9,000 patients in 18 ICUs with an intervention aimed at implementing barrier precautions (such as universal gloving until a patient's colonization status was known to be negative), carrying out active surveillance culturing, and feeding back adherence information to personnel; however, the net result of the intervention has been that, despite the improvement in compliance with precautions and procedures, no eff ect on colonization or infection rates was observed.
ASP may be another important tool to reduce and prevent AMR by selecting the most appropriate antibiotic choice with the least impact on microbial environment. Early diagnostic markers, information on the local epidemiology of AMR, and PK/PD indices for appropriate dosing and duration of anti microbial therapy are among the elements of an established ASP. Strictly interconnected with the infection control policy, these approaches represent the pillars of antimicrobial steward ship not only in the ICU but in the entire healthcare systems. Some interesting papers showing the importance and positive results of ASP carried out in diff erent settings have been reviewed in the last 2 years [42, 47] . Although the role of infectious disease specialists such as antimicrobial therapy experts within the ICU appears relevant in promoting and improving the quality of antibiotic prescription, clinical results of such approaches in terms of better patient outcome, reduction of AMR, and prevention of nosocomial transmission are still scanty. Th e excellent pro/con debate by George and Morris [48] in Critical Care clearly summarizes both the robust evidence to support the implementation of ASP and the diffi culty of demonstrating a real impact in terms of reduction of length of stay or mortality.
Fungal infections in the intensive care unit
Despite the availability of eff ective antifungal drugs, fungal infections remain a major concern in critically ill patients, mostly because of several predisposing factors occurring in ICU patients. Advances in medical care warrant improved survival to an ever-wider patient population with severe diseases while creating new subsets of patients at high risk for fungal infections. Both invasive candidiasis and asper gillosis often need surrogate markers of infection since proven diagnosis is still far from being the rule [49] . In addition, delaying the targeted antifungal treatment has been shown to further increase morbidity and mortality.
In an article in Critical Care, Bassetti and colleagues [50] reviewed the management of Candida infection in the ICU, providing updated considerations about issues in diagnosis, risk factors, adequate treatment, and the potential shift from Candida albicans to non-albicans strains because of widespread prophylactic use of fl ucona zole in the ICU. Th is shift may lead to in appropriate antifungal therapy whenever epidemio logical data at the local level are lacking. In France, Leroy and colleagues [51] conducted a multicenter study aiming at identifying clinical factors that could help distinguish between C. albicans and non-albicans fungemia epi sodes, thus guiding the choice of appropriate em pirical antifungal treatment. Only a few signifi cant diff erences were observed among the 136 patients ana lyzed: severity of underlying disease, the time to candi demia onset, and the rate of neutropenia. Accord ingly, the authors concluded that it was not possible to identify a reliable parameter to allow a binary distinction between albicans and nonalbicans candidemia or to guide the choice of antifungal therapy thereafter.
A shift in the paradigm of patient populations at risk for invasive aspergillosis has recently been described. For instance, a rising incidence of invasive bronchialpulmonary asper gillosis (IBPA) in non-neutropenic critically ill patients has been reported [52] . Critically ill patients are prone to develop impairments in immunoregulation during a stay in the ICU and thus are rendered more vulnerable to mold infections. Risk factors such as chronic obstructive respiratory disease (CORD), prolonged use of steroids, advanced liver disease, chronic renal replacement therapy, near-drowning, and diabetes mellitus have been described. Diagnosis of IBPA may be diffi cult, and obtaining histologic confi rmation to meet the gold standard for IBPA diagnosis is not always feasible in these patients, nor is the galactomannan test really useful in monitoring the development of IBPA in these patients. Recently, however, He and colleagues [53] prospectively evaluated 55 critically ill patients with CORD, including 13 who had IBPA. Th e authors' fi ndings indicate that more than three kinds of antibiotics used before ICU admission, high-dose steroids received before ICU admission, and APACHE II (Acute Physiology and Chronic Health Evaluation II) scores of greater than 18 were signifi cant independent risk factors for IBPA in the multivariate analysis. In such patients, IBPA may present as respira tory failure and clinical and bronchoscopic features of severe infection, bronchospasm, and rapid progression of radiologic lesions unresponsive to steroids and anti biotics. Despite the weaknesses of this study because of the small dataset (three predictor variables for 13 IBPA cases analyzed), the recommendations by the authors to perform early bronchoscopy and tight radiologic follow-up in order to avoid misdiagnosis and achieve micro biological confi rmation may be extended to other subsets of critically ill patients in the ICU with identifi ed risk factors for IBPA. Prospective studies aimed at improving the diagnosis and treatment of invasive fungal infections would certainly be welcomed by intensive care physicians.
Infl uenza A (H1N1) infection
Many data about the infl uenza A H1N1 pandemic were reported last year in Critical Care [1] ; however, some important advances on the topic have been described lately. First of all, the Global Infl uenza Programme of the World Health Organization analyzed and published pooled data collected from 19 countries or administrative regions [54] , including data from approxi mately 70,000 hospitalized patients with laboratory-confi rmed H1N1 diagnosis, 9,700 of whom were admitted to ICU and 2,500 of whom died. Risk factors were found to be similar to those for seasonal infl uenza but with some notable diff erences: cardiac or chronic respiratory illnesses and diabetes were important risk factors for severe disease, and the proportion of patients with H1N1 with one or more pre-existing chronic diseases increased with severity of infection. Th e proportion of H1N1 patients with one or more reported chronic conditions increased with severity (median = 31.1%, 52.3%, and 61.8% of hospitalized, ICU-admitted, and fatal H1N1 cases, respectively). Moreover, the analysis identifi ed obesity and younger age in comparison with seasonal infl uenza as additional risk factors. An important study from six Toronto hospitals [55] provided a multivariable logistic regression analysis to estimate the likelihood of H1N1 infl uenza in patients admitted to ICUs during pandemic waves: an admission temperature of at least 38°C and an admission diagnosis of pneumonia or respira tory infection were found to be independent predictors for infl uenza, and odds ratios for H1N1 were remarkably higher than those for seasonal infl uenza. Finally, researchers from the Guangdong Center for Disease Control and Prevention (China) [56] showed that early glucocorticoid treatment tripled the hazard of developing critical disease in hospitalized patients with confi rmed H1N1 infl uenza, once again highlighting the debated issue of glucocorticoid treatment in pulmonary infections.
Conclusions
During the last 18 months, Critical Care and other journals have provided a wide array of descriptive and interventional clinical studies and scientifi c papers helping clinical investigators and ICU clinicians to improve diagnosis, management, and therapy of infections in the ICU setting. We are confi dent that exciting progress will continue to be made, especially in the fi eld of rapid diagnostics of infections in critically ill patients.
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